Genes (40)
Species: human : 40 | |
Human | SOX6 | 55553 | SRY (sex determining region Y)-box 6 | Immunohistochemical analysis with the anti-SOX6 antibody showed that all the glioma tissues analyzed (14 glioblastomas, 14 anaplastic astrocytomas, 3 anaplastic oligoastrocytomas, 5 diffuse astrocytomas, 1 oligodendroglioma, and 1 pilocytic astrocytoma) expressed SOX6 in tumor cells, but only a few SOX6-positive cells were detected in nonneoplastic tissues from the cerebral cortex. | Human | ADAM28 | 10863 | ADAM metallopeptidase domain 28 | In this work, we have examined the expression level and the methylation status of the 5; upstream region of the adhesion molecule ADAM23 in two brain tumor cell lines (A172 and T98G) as well as in three primary brain tumors (one grade II astrocytoma and two meningiomas) and 15 glioblastoma xenografts. | Human | OLIG2 | 10215 | oligodendrocyte lineage transcription factor 2 | (2001) Lancet 358:298-300]. We investigated the mRNA expression of OLIG1 and OLIG2, as well as four other genes involved in oligodendrocyte development ( E2A, HEB, NKX2.2, and PDGFRA) in a panel of 70 gliomas, including 9 oligodendrogliomas, 11 anaplastic oligodendrogliomas, 5 oligoastrocytomas, 10 anaplastic oligoastrocytomas, 10 diffuse astrocytomas, 10 anaplastic astrocytomas, and 15 glioblastomas. | Human | TNFRSF6B | 8771 | tumor necrosis factor receptor superfamily, member 6b, decoy | Expression of DcR3 correlates with the grade of malignancy: 15 of 18 (83%) glioblastomas (WHO grade IV) but none of 11 diffuse astrocytomas (WHO grade II) exhibited DcR3 immunoreactivity. | Human | HRK | 8739 | harakiri, BCL2 interacting protein (contains only BH3 domain) | The region around the HRK transcription start site was methylated in 19% of diffuse astrocytomas, in 22% of anaplastic astrocytomas, in 27% of primary glioblastomas, and in 43% of secondary glioblastomas. | Human | TXN | 7295 | thioredoxin | Diffuse astrocytomas showed more intense staining for Trx (p = 0.002), TrxR (p = 0.004), GLCL-c (p = 0.001), GLCL-r (p = 0.04) and MnSOD (p = 0.01) than pilocytic astrocytomas. Within diffuse astrocytomas only Trx (p = 0.0001) and TrxR (p= 0.04) significantly associated with increased malignancy grade. Expression of Trx and lack of MnSOD expression was associated with a worse prognosis in diffuse astrocytomas. | Human | TOP2A | 7153 | topoisomerase (DNA) II alpha 170kDa | These analyses confirmed that the transcript levels of nine of the selected genes (COL4A2, FOXM1, MGP, TOP2A, CENPF, IGFBP4, VEGFA, ADD3, and CAMK2G) differed significantly in WHO grade II astrocytomas as compared to anaplastic astrocytomas and/or glioblastomas. | Human | TERC | 7012 | telomerase RNA component | Interestingly, increased telomerase RNA levels were observed in a subgroup of grade II astrocytomas that showed significant increase in proliferation activity (P = 0.047), indicating that the telomerase RNA component is up-regulated already in early states of astrocytoma malignancy. | Human | TCF12 | 6938 | transcription factor 12 | (2001) Lancet 358:298-300]. We investigated the mRNA expression of OLIG1 and OLIG2, as well as four other genes involved in oligodendrocyte development ( E2A, HEB, NKX2.2, and PDGFRA) in a panel of 70 gliomas, including 9 oligodendrogliomas, 11 anaplastic oligodendrogliomas, 5 oligoastrocytomas, 10 anaplastic oligoastrocytomas, 10 diffuse astrocytomas, 10 anaplastic astrocytomas, and 15 glioblastomas. | Human | TCF3 | 6929 | transcription factor 3 | (2001) Lancet 358:298-300]. We investigated the mRNA expression of OLIG1 and OLIG2, as well as four other genes involved in oligodendrocyte development ( E2A, HEB, NKX2.2, and PDGFRA) in a panel of 70 gliomas, including 9 oligodendrogliomas, 11 anaplastic oligodendrogliomas, 5 oligoastrocytomas, 10 anaplastic oligoastrocytomas, 10 diffuse astrocytomas, 10 anaplastic astrocytomas, and 15 glioblastomas. | Human | SYP | 6855 | synaptophysin | We have investigated the expression of microtubule associated protein 2 (MAP-2), synaptophysin and non-phosphorylated epitopes of neurofilament protein (NFP) by immunohistochemistry in 15 low grade diffuse astrocytomas and 15 glioblastomas. Histologically, nodules of small neuronal tumor cells immunoreactive for synaptophysin and NeuN were embedded within a diffuse astrocytoma. | Human | SOD2 | 6648 | superoxide dismutase 2, mitochondrial | Diffuse astrocytomas showed more intense staining for Trx (p = 0.002), TrxR (p = 0.004), GLCL-c (p = 0.001), GLCL-r (p = 0.04) and MnSOD (p = 0.01) than pilocytic astrocytomas. Expression of Trx and lack of MnSOD expression was associated with a worse prognosis in diffuse astrocytomas. | Human | PTGS2 | 5743 | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | These results implicate COX-2 in the angiogenesis and biological aggressiveness of diffuse astrocytomas | Human | PAX5 | 5079 | paired box 5 | In primary human diffuse astrocytomas, PAX5 expression inversely correlated with p53 expression. | Human | NME4 | 4833 | NME/NM23 nucleoside diphosphate kinase 4 | Expression of six genes (TIMP3, c-myc, EGFR, DR-nm23, nm23-H4, and GDNPF) was detected in 64-100% of diffuse astrocytomas, but not in nontumorous brain tissue. | Human | NME3 | 4832 | NME/NM23 nucleoside diphosphate kinase 3 | Expression of six genes (TIMP3, c-myc, EGFR, DR-nm23, nm23-H4, and GDNPF) was detected in 64-100% of diffuse astrocytomas, but not in nontumorous brain tissue. | Human | NME1 | 4830 | NME/NM23 nucleoside diphosphate kinase 1 | Eight diffuse astrocytomas and 19 glioblastomas (WHO IV) were analyzed to determine if TIMP-1 and NM23-H1 were candidates to inhibition of tumor cell invasion quantitated RNA levels. NM23-H1 was present in the entire gliomas sample, but it did not vary in diffuse astrocytomas and glioblastomas. PURPOSE: To evaluate using transcription analysis the presence and importance of two genes: NM23-H1 and TIMP-1 on control of tumor cell invasion in diffuse astrocytomas (WHO II) and glioblastoma multiforme (WHO IV). | Human | MGMT | 4255 | O-6-methylguanine-DNA methyltransferase | immunohistochemical MGMT assessment has potential as a powerful diagnostic tool but analysis should only be performed in a grade dependent manner, before radio-/chemotherapy and with special attention to the infiltration zone of diffuse astrocytomas | Human | MCM3 | 4172 | minichromosome maintenance complex component 3 | The expression of one of the identified antigens, the replication licensing factor minichromosome maintenance protein 3 (MCM3), was analyzed by immunohistochemistry in 142 primary and 27 recurrent astrocytomas (WHO grades 2-4). Expression of MCM3 in diffuse astrocytoma is significantly associated with age (P < 0.001), histologic grade (P < 0.001), time to recurrence (P = 0.01), and expression of the proliferation marker Ki-67 (P < 0.001) but not with sex (P = 0.800). | Human | MCM2 | 4171 | minichromosome maintenance complex component 2 | There was a significant increase in Mcm-2 (P < 0.0001), Ki67 (P < 0.0001), cyclin A (P < 0.0001) and cyclin B1 (P = 0.002) expression with increasing grade from diffuse astrocytoma through anaplastic astrocytoma to glioblastoma, suggesting that any of these four markers has potential as a marker of tumour grade. Paraffin-embedded sections of intracerebral gliomas (n = 48), consisting of diffuse astrocytoma (n = 9), anaplastic astrocytoma (n = 8) and glioblastoma (n = 31), were analysed by immunohistochemistry using markers of cell cycle entry, Mcm-2 and Ki67, and putative markers of cell cycle phase, cyclins D1 (G1-phase), cyclin A (S-phase), cyclin B1 (G2-phase) and phosphohistone H3 (Mitosis). | Human | MAP2 | 4133 | microtubule-associated protein 2 | Compared to ;classical; variants of diffuse astrocytomas (WHO grade II), immunohistochemical reactions revealed a cellular proliferation below 1%, absence of nuclear p53 accumulation, and a lack of glial MAP2 and CD34 expression. Microtubule-associated protein 2 (MAP-2) is expressed in low and high grade diffuse astrocytomas. We have investigated the expression of microtubule associated protein 2 (MAP-2), synaptophysin and non-phosphorylated epitopes of neurofilament protein (NFP) by immunohistochemistry in 15 low grade diffuse astrocytomas and 15 glioblastomas. | Human | IGFBP4 | 3487 | insulin-like growth factor binding protein 4 | These analyses confirmed that the transcript levels of nine of the selected genes (COL4A2, FOXM1, MGP, TOP2A, CENPF, IGFBP4, VEGFA, ADD3, and CAMK2G) differed significantly in WHO grade II astrocytomas as compared to anaplastic astrocytomas and/or glioblastomas. | Human | IGFBP2 | 3485 | insulin-like growth factor binding protein 2, 36kDa | Strong expression of IGFBP2 was associated with progression and poor patient survival in diffuse astrocytomas (P < 0.0001). | Human | IDH1 | 3417 | isocitrate dehydrogenase 1 (NADP+), soluble | Data show that the very high frequency of IDH1 mutations occurrs in diffuse astrocytomas, oligodendrogliomas, oligoastrocytomas and secondary glioblastomas | Human | HIF1A | 3091 | hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | HIF-1alpha expression may be used to refine the prognostic information provided by grade in patients with diffuse astrocytomas. Expression of HIF-1alpha, VEGF, Ki-67 (a proliferation-associated marker) and p53 was determined immunohistochemically in 83 adult patients with supratentorial diffuse astrocytomas. HIF-1alpha expression may be used to refine the prognostic information provided by grade in patients with diffuse astrocytomas The aim of this study was to determine the relation of HIF-1alpha to vascular endothelial growth factor (VEGF; an important angiogenic molecule in brain tumours), p53 expression, angiogenesis, proliferative potential and clinical outcome in a large series of diffuse astrocytomas. |
|